tbuckley/cabot-search huggingface dataset:
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
Authors: Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal
Journal: Blood (2022)
FULFILMENT ANALYSIS OF QUALITY STANDARDS, STABLISHED BY THE EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY, IN SMALL-BOWEL CAPSULE ENDOSCOPY IN SPANISH CENTERS
Authors: M Gómez Villagrá, C. Prieto, D. Acitores, M Alonso, N Alonso, N Caballero, F Sánchez Ceballos, L Compañy, J Egea, P Esteban, S Farrais, I Fernandez-Urien, C Galvez, A García, J Garcia LLedo, B Gonzalez, A Jimenez, M Lujan, B Mateos, C Romero, M San Juan, E Valdivieso, C Carretero
Journal: Endoscopy (2022)

Aims In 2019 the working group of the European Society of Gastrointestinal Endoscopy(ESGE) was reunited with the objective of developing technical and quality standards for small- bowel endoscopy, in order to improve the daily practice in the endoscopy services.
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Authors: Samuel M. Rubinstein, Divaya Bhutani, Ryan C. Lynch, Chih-Yuan Hsu, Yu Shyr, Shailesh Advani, Ruben A. Mesa, Sanjay Mishra, Daniel P. Mundt, Dimpy P. Shah, R. Alejandro Sica, Keith E. Stockerl-Goldstein, Catherine Stratton, Matthias Weiss, Alicia Beeghly-Fadiel, Melissa Accordino, Sarit E. Assouline, Joy Awosika, Ziad Bakouny, Babar Bashir, Stephanie Berg, Mehmet Asim Bilen, Cecilia A. Castellano, Jacob C. Cogan, Devendra KC, Christopher R. Friese, Shilpa Gupta, Daniel Hausrath, Clara Hwang, Nathalie A. Johnson, Monika Joshi, Anup Kasi, Elizabeth J. Klein, Vadim S. Koshkin, Nicole M. Kuderer, Daniel H. Kwon, Chris Labaki, Tahir Latif, Eric Lau, Xuanyi Li, Gary H. Lyman, Rana R. McKay, Gayathri Nagaraj, Amanda Nizam, Taylor K. Nonato, Adam J. Olszewski, Hyma V. Polimera, Andrew J. Portuguese, Matthew M. Puc, Pedram Razavi, Rachel Rosovski, Andrew Schmidt, Sumit A. Shah, Aditi Shastri, Christopher Su, Pallawi Torka, Trisha M. Wise-Draper, Leyre Zubiri, Jeremy L. Warner, Michael A. Thompson
Journal: Blood Cancer Discovery (2022)

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.
Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals
Authors: Zi-Wei Ye, Chon Phin Ong, Kaiming Tang, Yilan Fan, Cuiting Luo, Runhong Zhou, Peng Luo, Yun Cheng, Victor Sebastien Gray, Pui Wang, Hin Chu, Jasper Fuk-Woo Chan, Kelvin Kai-Wang To, Honglin Chen, Zhiwei Chen, Kwok-Yung Yuen, Guang Sheng Ling, Shuofeng Yuan, Dong-Yan Jin
Journal: Cellular and Molecular Immunology (2022)
Amino Acid Uptake, Glucose Metabolism, and Neuroinflammation in John Cunningham Virus Associated Progressive Multifocal Leukoencephalopathy
Authors: Marcus Unterrainer, Christoph Mahler, Adrian-Minh Schumacher, Viktoria Ruf, Bernhard Blum, Stefanie Quach, Matthias Brendel, Rainer Rupprecht, Peter Bartenstein, Martin Kerschensteiner, Tania Kümpfel, Nathalie L. Albert
Journal: Clinical Nuclear Medicine (2022)

Abstract A 69-year-old woman presented with progressive dysarthria and cognitive deficits. On MRI, a T2-hyperintense, non–contrast-enhancing lesion was found in the left precentral area. 18 F-FET and 18 F-FDG PET scans revealed faint amino acid uptake and glucose hypometabolism of the lesion. To assess a neuroinflammatory component, TSPO PET with 18 F-GE-180 was performed, where tracer uptake markedly exceeded the T2-hyperintense areas. Histology derived from a stereotactic biopsy findings confirmed John Cunningham virus–associated progressive multifocal leukoencephalopathy. This case underlines that TSPO PET comprises distinct imaging advantages over other established radioligands such as 18 F-FET and 18 F-FDG in progressive multifocal leukoencephalopathy.
ENDOSCOPIC ULTRASOUND(EUS) GUIDED SPLENIC ARTERY PSEUDOANEURYSM COILING IN CHRONIC CALCIFIC PANCREATITIS WITH HEMOSUCCUS PANCREATICUS
Authors: A. Kulkarni, V. Kulkarni, M. Kulkarni, A. Deshpande
Journal: Endoscopy (2022)

AIM: Hemosuccus pancreaticus is serious complication of chroniccalcificpancreatitis.Current management is angiographic coil embolization of the pseudoaneurysm.We present case of hemossuccus pancreaticus managed successfully by EUS guided coil embolization followed by glue injection.40yearmale,known case of chronic calcificpancreatitis presented with melena and required transfusions.UpperGIendoscopy showed blood oozing through the papilla.TriplephaseCT showed CCP,with1.2cm pseudoaneurysm arising from splenic artery.On EUS,pseudoaneurysm was identified and punctured by 19Gneedle,10mmx14cm coil was inserted followed by 0.5cc of N-butrylcynoacryolate glue.Complete obliteration of pseudoaneurysm was confirmed on Doppler.Post procedure patient was hemodynamically stable
EQUIVALENT EFFICACY AND SAFETY OF PLASTIC STENTS AND LAMS IN THE TREATMENT OF PERIPANCREATIC FLUID COLLECTION; A PROSPECTIVE STUDY
Authors: K. Khodakaram, P. Hedenström, S.-O. Bratlie, R. Sadik
Journal: Endoscopy (2022)

Aims Endoscopic ultrasound (EUS)-guided transmural drainage using plastic stents (PS) has been routine for the treatment of peripancreatic fluid collection (PFC). Since 2016 lumen-apposing metal stents (LAMS) have been introduced aiming for better draining efficacy. The aim of this long-term prospective study was to compare the efficacy and safety of PS vs LAMS.
250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
Authors: J. Lu, G.T. Budd, S. Frentzas, H. Park, C. Shannon, H.S. Rugo, J. O'Shaughnessy, A. Demichele, S.M. Tolaney, R.W. Eek, A. McCartney, K. Cuff, L. Esserman, A. Alika, D. Xu, M. Li, T. Le, D.Z. L'Heureux, J. Yan, S.A. Hurvitz
Journal: Annals of Oncology (2022)
230P A digital therapeutic intervention for breast cancer patients during active treatment: A feasibility study
Authors: G.E. Thorvardardottir, H. Gudmundsson, J. Mészáros, A.E. Bjornsdottir, M.L. Amundadottir, O.K. Bjarnadottir, E. Magnusdottir, H. Helgadottir, S. Oddsson
Journal: Annals of Oncology (2022)
IMPACT OF EUS-GUIDED BILIARY DRAINAGE AND GASTROJEJUNOSTOMY IN COMBINED MALIGNANT BILIARY AND GASTRIC OUTLET OBSTRUCTION
Authors: L. Sanchez-Delgado, F.J. Garcia-Alonso, M. Villarroel, M. Cimavilla, A.Y. Carbajo, R. Busta Nistal, J. Estradas, M. de Benito Sanz, C. de la Serna-Higuera, M. Perez-Miranda
Journal: Endoscopy (2022)

Aims Combined malignant gastric outlet obstruction (GOO) and biliary obstruction remain a challenge. EUS-guided biliary transmural drainage (EUS-BD) and gastrojejunal anastomoses (EUS-GJ) are already available alternatives. Comparatives of intraluminal and transmural approaches are scarce.
RECTAL MIGRATION OF AN UROLOGIC HEM-O-LOK CLIP
Authors: E. Pijoan Comas, D.C. Bayas Pástor, N. Torres Monclús, A. Vargas García, D. Vázquez Gómez, G. Torres Vicente, I. Miguel Salas, M. Alburquerque Miranda, N. Zaragoza Velasco, F. Gonzalez-Huix Lladó
Journal: Endoscopy (2022)

A 64-year-old man with previous robotic radical prostatectomy for prostate adenocarcinoma underwent colonoscopy for colonic polyp surveillance. A hard nodular lesion was found in rectum, that was resected with cold snare, showing a residual white base. Resection was tried with cold snare, biopsy forceps and band ligation mucosectomy without success. Biopsies of the base showed normal mucosa. At 3 months control, a foreign body was found in rectum, in the previous nodular area, that seemed a non-absorbable polymeric ligation clip (Hem-o-lok), used in the prostatic surgery. The clip was not removed and had migrated spontaneously at 3 months control.
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma
Authors: Caitlin M. O'Connor, Sarah E. Taylor, Kathryn M. Miller, Lauren Hurst, Terrance J. Haanen, Tahra K. Suhan, Kaitlin P. Zawacki, Fallon K. Noto, Jonida Trako, Arathi Mohan, Jaya Sangodkar, Dmitriy Zamarin, Analisa DiFeo, Goutham Narla
Journal: Cancer Research (2021)

Abstract Uterine serous carcinoma (USC) is a highly aggressive endometrial cancer subtype with limited therapeutic options and a lack of targeted therapies. While mutations to PPP2R1A, which encodes the predominant protein phosphatase 2A (PP2A) scaffolding protein Aα, occur in 30% to 40% of USC cases, the clinical actionability of these mutations has not been studied. Using a high-throughput screening approach, we showed that mutations in Aα results in synthetic lethality following treatment with inhibitors of ribonucleotide reductase (RNR). In vivo, multiple models of Aα mutant uterine serous tumors were sensitive to clofarabine, an RNR inhibitor (RNRi). Aα-mutant cells displayed impaired checkpoint signaling upon RNRi treatment and subsequently accumulated more DNA damage than wild-type (WT) cells. Consistently, inhibition of PP2A activity using LB-100, a catalytic inhibitor, sensitized WT USC cells to RNRi. Analysis of The Cancer Genome Atlas data indicated that inactivation of PP2A, through loss of PP2A subunit expression, was prevalent in USC, with 88% of patients with USC harboring loss of at least one PP2A gene. In contrast, loss of PP2A subunit expression was rare in uterine endometrioid carcinomas. While RNRi are not routinely used for uterine cancers, a retrospective analysis of patients treated with gemcitabine as a second- or later-line therapy revealed a trend for improved outcomes in patients with USC treated with RNRi gemcitabine compared with patients with endometrioid histology. Overall, our data provide experimental evidence to support the use of ribonucleotide reductase inhibitors for the treatment of USC. Significance: A drug repurposing screen identifies synthetic lethal interactions in PP2A-deficient uterine serous carcinoma, providing potential therapeutic avenues for treating this deadly endometrial cancer.
Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs Pathology
Authors: Alexander S. Szalay, Janis M. Taube
Journal: Clinical Cancer Research (2022)

Abstract Astronomy was among the first disciplines to embrace Big Data and use it to characterize spatial relationships between stars and galaxies. Today, medicine, in particular pathology, has similar needs with regard to characterizing the spatial relationships between cells, with an emphasis on understanding the organization of the tumor microenvironment. In this article, we chronicle the emergence of data-intensive science through the development of the Sloan Digital Sky Survey and describe how analysis patterns and approaches similarly apply to multiplex immunofluorescence (mIF) pathology image exploration. The lessons learned from astronomy are detailed, and the new AstroPath platform that capitalizes on these learnings is described. AstroPath is being used to generate and display tumor-immune maps that can be used for mIF immuno-oncology biomarker development. The development of AstroPath as an open resource for visualizing and analyzing large-scale spatially resolved mIF datasets is underway, akin to how publicly available maps of the sky have been used by astronomers and citizen scientists alike. Associated technical, academic, and funding considerations, as well as extended future development for inclusion of spatial transcriptomics and application of artificial intelligence, are also addressed.
MOTORIZED SPIRAL ENTEROSCOPY IN PATIENTS WITH PRIOR ABDOMINAL SURGERY: A MULTICENTER OBERVATIONAL STUDY
Authors: A. Giordano, L. Compañy, F.A. Ruiz-Gómez, M. Urpi-Ferreruela, P. Fernández-Gil, N. Alonso-Lázaro, J. Sola Vera, M. Aicart, S. Parejo Carbonell, C. Carretero, C. Prieto, M. Escapa, V. Pons, B. González-Suárez
Journal: Endoscopy (2022)

Aims Motorized Spiral Enteroscopy (MSE) reduces procedure time and increases insertion depth into the small bowel, however there is scarce evidence on factors affecting MSE efficacy. This multicenter study aimed at evaluating diagnostic yield and adverse events of MSE in patients with prior abdominal surgery.
148P Descriptive study of mutation status and clinical phenotype in breast cancer patients of South Catalonia
Authors: A. Cochs, M. Rodriguez Balada, B. Roig Bourgine, S. Fernández Castillejo, C.R. Albacar Miro, L. Delamo Palomares, M. Querol Garcia, M. Salvat Casas, J. Repkova, M. Masvidal Hernandez, S. Serrano Solares, K. Amillano Parraga, M. Mele Olive, J. Gumà
Journal: Annals of Oncology (2022)
113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials
Authors: T. Ruelle, M. Perachino, E. Blondeaux, M. Bruzzone, A. Fozza, A. Garlaschi, L. Belgioia, F. Pitto, A. Levaggi, M. Sparavigna, L. Del Mastro, M. Lambertini, P. Fregatti
Journal: Annals of Oncology (2022)
14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
Authors: N. Teng, M.J. Dalby, R. Kiu, T. Robinson, M. Gion Cortes, B. Bermejo De Las Heras, J.M. Perez Garcia, L. Calvo-Martinez, A. Prat, R. Marquez Vazquez, M. Ruiz Borrego, S. de la Cruz, A. Llombart Cussac, G. Curigliano, P. Schmid, M. Mancino, L. Hall, S. Robinson, J. Cortés, A. Malfettone
Journal: Annals of Oncology (2022)
140P A study on assessment of barriers to genetic counselling and testing among breast and ovarian cancer patients in a tertiary referral hospital in India
Authors: I. Siripurapu, V.V. Maka, S. Majumdar, R. Palassery, N. Elackatt, A.D. Mandade, T. Adadadara, S. Pathak, C. Agrawal, P. Jayaprakash, P.P. Manmatha, S. Kumar
Journal: Annals of Oncology (2022)
Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study
Authors: Georg Semmler, Alexander Lindorfer, Benedikt Schäfer, Stefan Bartl, Stephanie Hametner-Schreil, Sophie Gensluckner, Lorenz Balcar, Katharina Pomej, Katharina Lampichler, Michael Trauner, Elmar Aigner, Christian Datz, Heinz Zoller, Harald Hofer, Rainer Schöfl, Mattias Mandorfer, Thomas Reiberger, Bernhard Scheiner
Journal: Clinical Gastroenterology and Hepatology (2022)
HIGH PROFICIENCY OF ESOPHAGEAL ENDOSCOPIC SUBMUCOSAL DISSECTION WITH A “TUNNEL+CLIP” STRATEGY: A LARGE FRENCH MULTICENTRIC STUDY
Authors: T. Wallenhorst, J. Jacques, C. Brochard, R. Legros, H. Lepetit, M. Barret, J. Rivory, M. Pioche, A. Lupu, S. Stephant
Journal: Endoscopy (2022)

Aims Esophageal endoscopic submucosal dissection (ESD) is the gold standard for the treatment of precancerous lesions or superficial esophageal cancers. This procedure is currently performed by expert endoscopists only, and poorly standardized. We aimed to assess the technical results and outcomes of a “tunnel+clip” strategy for esophageal ESD procedures performed by less experienced operators for the treatment of superficial neoplasms.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report
Authors: Liora M. Schultz, Christina Baggott, Snehit Prabhu, Holly L. Pacenta, Christine L. Phillips, Jenna Rossoff, Heather E. Stefanski, Julie-An Talano, Amy Moskop, Steven P. Margossian, Michael R. Verneris, Gary Douglas Myers, Nicole A. Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A. Rabik, Vanessa A. Fabrizio, Rayne H. Rouce, Vasant Chinnabhandar, Michael Kunicki, Valentin V. Barsan, A. Yasemin Goksenin, Yimei Li, Sharon Mavroukakis, Emily Egeler, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch
Journal: Journal of Clinical Oncology (2021)

Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, and young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic leukemia (B-ALL). The US Food and Drug Administration registration for tisagenlecleucel was based on a complete response (CR) rate of 81%, 12-month overall survival (OS) of 76%, and event-free survival (EFS) of 50%. We report clinical outcomes and analyze covariates of outcomes after commercial tisagenlecleucel.We conducted a retrospective, multi-institutional study of CAYA with RR B-ALL across 15 US institutions, who underwent leukapheresis shipment to Novartis for commercial tisagenlecleucel. A total of 200 patients were included in an intent-to-treat response analysis, and 185 infused patients were analyzed for survival and toxicity.Intent-to-treat analysis demonstrates a 79% morphologic CR rate (95% CI, 72 to 84). The infused cohort had an 85% CR (95% CI, 79 to 89) and 12-month OS of 72% and EFS of 50%, with 335 days of median follow-up. Notably, 48% of patients had low-disease burden (< 5% bone marrow lymphoblasts, no CNS3, or other extramedullary disease), or undetectable disease, pretisagenlecleucel. Univariate and multivariate analyses associate high-disease burden (HB, ≥ 5% bone marrow lymphoblasts, CNS3, or non-CNS extramedullary) with inferior outcomes, with a 12-month OS of 58% and EFS of 31% compared with low-disease burden (OS; 85%, EFS; 70%) and undetectable disease (OS; 95%, EFS; 72%; P < .0001 for OS and EFS). Grade ≥ 3 cytokine release syndrome and neurotoxicity rates were 21% and 7% overall and 35% and 9% in patients with HB, respectively.Commercial tisagenlecleucel in CAYA RR B-ALL demonstrates efficacy and tolerability. This first analysis of commercial tisagenlecleucel stratified by disease burden identifies HB preinfusion to associate with inferior OS and EFS and increased toxicity.
COLD ENDOSCOPIC MUCOSAL RESECTION OF A LARGE LATERALLY SPREADING LESION TUBULOVILLOUS ADENOMA WITH LONG-TERM FOLLOW-UP
Authors: A.O. Kheir
Journal: Endoscopy (2022)

A 64-year-old male with 46mm, Paris IIa, granular laterally spreading lesion at the mid-rectum. NBI showed high-confidence NICE classification type 2. A prophylactic broad-spectrum antibiotic was given. We performed piecemeal cold endoscopic mucosal resection (CEMR) technique using 10-mm size dedicated cold snare. No clips were needed. Regular diet was resumed immediately and home discharge 2-hours post CEMR. No post-discharge complications. Histology confirmed tubulovillous adenoma. Post-CEMR surveillance was performed after 18-months due to the COVID pandemic. The CEMR scar showed normal regenerative mucosa without endoscopic evidence or histologic evidence of residual neoplasia. CEMR is effective long-term for selected large flat adenomas.
INCIDENCE OF PANCREATIC CANCER WITHIN PANCREATIC CYSTIC NEOPLASM: 6-YEAR RESULTS FROM A NATIONWIDE PATHOLOGY DATABASE
Authors: N. van Huijgevoort, M. Gorris, A. Farina Sarasqueta, L. Brosens, H. van Santvoort, B. Groot Koerkamp, M. Bruno, M. Besselink, J. van Hooft
Journal: Endoscopy (2022)

Aims Pancreatic cystic neoplasms (PCN) are known precursor lesions for pancreatic ductal adenocarcinoma (PDAC) and thereby pose an opportunity for early detection and curative treatment. The aim of this national retrospective study was to investigate the incidence of PDAC arising from PCN in the Netherlands.
ACCURACY IMPROVEMENT OF RECONSTRUCTED 3-DIMENSIONAL COLONOSCOPE DISPLAY APPLYING FIBER BRAGG GRATING SENSOR
Authors: J. Park, B. Keum, J. Shim, G. Park, J. Yoon, E.J. Bang, K.W. Lee, S.H. Kim, H.J. Jeon, J.M. Lee, H.S. Choi, E.S. Kim, Y.T. Jeen, H.S. Lee, H.J. Chun
Journal: Endoscopy (2022)

Aims Fiber brag grating (FBG) sensor is a detector that irradiates a laser to the core fiber of an optic fiber and measures the difference in wavelength due to changes in the length and strain of the fiber. However, there was a problem in realizing an accurate colonoscope shape in 3-dimensional (3D) display due to a signal generated from a site not inserted into the colonoscope. Therefore, this study aims to increase the precision of the length and shape of the 3D colonoscope by applying the technology of selectively turning the sensor on/off based on the anus using the FBG sensor.
ENDORAIL ADD-ON DEVICE FOR SOLVING COLON LOOPS: PROOF OF CONCEPT IN A PHANTOM COLON. ​​
Authors: A. Repici, M. Spadaccini, E. Vespa, P. Bhandari, P. Sharma, R. Maselli, C. Hassan
Journal: Endoscopy (2022)

Aims Incomplete colonoscopy can result in missed colorectal cancer. Looping is a main cause for difficult and incomplete colonoscopy. The aim of this study is to assess the capability of Endorail to solve colon loops in a phantom model.
FULLY-COVERED SELF-EXPANDABLE METAL STENTS (FCSEMS) AS RESCUE TREATMENT FOR POST-SPHINCTEROTOMY BLEEDING AND BILE DUCT PERFORATION. A CASE SERIES FROM A GREEK REFERRAL CENTRE
Authors: G. Kranidiotis, N. Tsoukalas, A. Trikola, A. Kazamias, M. Ellina, N. Kotsikoros, M. Rodias, G. Stefanidis
Journal: Endoscopy (2022)

Aims FCSEMS have been used as a «rescue treatment» for several urgent biliary tract conditions. This study evaluated the efficacy, safety, and duration of stenting with FCSEMS in extremely high-risk conditions: post-sphincterotomy bleeding and bile duct perforations.
INTERVAL CANCER IN DANISH COLORECTAL CANCER SCREENING PARTICIPANTS WITH FAECAL IMMUNOCHEMICAL TEST VALUES BELOW 10 MICROGRAM OF HAEMOGLOBIN PER GRAM OF FAECES
Authors: U. Deding, E. Plantener, J.B. Madsen, I. Al-Najami, L. Kaalby, M. Kobaek-Larsen, T. Bjørsum-Meyer, G. Baatrup
Journal: Endoscopy (2022)

Aims A faecal immunochemical test (FIT) value threshold of 20 microgram haemoglobin per gram (μg hb/g) faeces has been set in the Danish colorectal cancer (CRC) screening program (90% have FIT-values<10). We aimed to investigate the incidence rate (IR) of interval CRC and other cancers in this population stratified by FIT-value.
48P T-helper cell-driven immune response as an effect for seroma formation (SF) after mastectomy (ME) in breast cancer (BC) (SerMa pilot EUBREAST 5)
Authors: N. Ditsch, M. Schneider, N. Pochert, N. Ansorge, A. Strieder, J. Sagasser, T. Kühn, A. Neumann, M. Reiger, C. Traidl-Hoffmann, U. Jeschke, C. Dannecker
Journal: Annals of Oncology (2022)